Form 4 for CGEM Cullinan Therapeutics, Inc.
Accepted 2026-05-06 17:00:27 ET · period of report 2026-05-05 · accession 0001193125-26-209307 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-05-06 17:00 | 2026-05-05 | CGEM | Michaelson Jennifer | CSO | M - OptEx | $4.30 | +4,000 | 174.8K | +2% | +$17.2K |
| DMT | 2026-05-06 17:00 | 2026-05-05 | CGEM | Michaelson Jennifer | CSO | S - Sale+OE | $14.62 | -8,000 | 166.8K | -5% | -$117.0K |
| DT | 2026-05-06 17:00 | 2026-05-05 | CGEM | Michaelson Jennifer | CSO | M - OptEx | $0.00 | -4,000 | 117.0K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-05 | M | A | 4,000 | $4.30 | 174,844 | D | — | — | |
| 2 | Common | Common Stock | 2026-05-05 | S | D | 7,800 | $14.60 | 167,044 | D | — | — | (F1) Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.24 to $15.12. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-05-05 | S | D | 200 | $15.58 | 166,844 | D | — | — | (F1) Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.56 to $15.60. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-05-05 | M | D | 4,000 | $0.00 | 116,987 | D | $4.30 · — to 2030-10-28 | 4,000 Common Stock | (F4) 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter. |